Durect Investors Feel the Pain

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Durect (Nasdaq: DRRX  ) investors just got a painful reminder of what happens when an important drug candidate fails a phase 3 trial.

When post-surgery pain reliever Posidur failed to meet its primary endpoint, shares were promptly slashed by a third. That's life in spec pharma. The trial, named BESST, gave the worst possible results: Posidur failed to show statistical significance in reducing pain. But hey, at least it was shown to be safe!

Durect will huddle up with partner Hospira (NYSE: HSP  ) and chat with the FDA, but it's pretty bleak. Although one group reported taking 16% less opioids, it doesn't matter since the drug ended up with a mean reduction in pain scores of just 7%. Ouch!

This isn't the end of the line for Durect. It has two products on the market and its extended-release and abuse-resistant technologies can still be licensed out, but it needs to start winning. Shares have fallen 75% since top drug candidate Remoxy, partnered with Pfizer (NYSE: PFE  ) and Pain Therapeutics (Nasdaq: PTIE  ) , suffered a huge setback last summer when the FDA rejected it due to manufacturing concerns. Pain Therapeutics said it didn't know whether the irregularities were caused by the actual manufacturing or how the drug was measured in the different lots. Keep in mind this is a drug the trio has been trying to get approved since 2008.

But the FDA isn't against improved painkillers. The month prior and the month after, two similar drugs were approved, one by Johnson & Johnson and another by Pfizer and partner Acura Pharmaceuticals (Nasdaq: ACUR  ) , each of which overcame initial setbacks. The troubles with Acura's drug Oxecta were with the formulation, so it's not completely analogous, but hopefully Pfizer's experience in navigating these waters can help speed along Remoxy.

Beyond Remoxy, Durect has two drugs in phase 2 trials, two more in phase 1, and one preclinical candidate. Bottom line, Posidur was the company's nearest-term candidate of moving the needle. Now investors are resting their hats on the ability to get Remoxy's issues finally straightened out and past the FDA along with some compounds that are years away. Today's sell-off is justified as there are probably better places to put your money in the meantime.

In fact, Motley Fool co-founder David Gardner has found a small health-care stock on the cusp of blockbuster growth and is offering to share it with you for free in our special report "Discover the Next Rule-Breaking Multibagger." Available for a limited time, download this must-read special free report right now and don't miss your opportunity for market-beating returns.

David Williamson owns shares of Johnson & Johnson and Pfizer, but he holds no other position in any company mentioned. Click here to see his holdings and a short bio. The Motley Fool owns shares of Johnson & Johnson. Motley Fool newsletter services have recommended buying shares of Pfizer and Johnson & Johnson and creating a diagonal call position in Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Read/Post Comments (0) | Recommend This Article (3)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 1753811, ~/Articles/ArticleHandler.aspx, 10/24/2016 12:05:01 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,235.29 89.58 0.49%
S&P 500 2,150.50 9.34 0.44%
NASD 5,303.10 45.70 0.87%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

10/24/2016 11:49 AM
DRRX $1.20 Down -0.02 -1.64%
DURECT CAPS Rating: **
ACUR $1.17 Down -0.01 -0.76%
Acura Pharmaceutic… CAPS Rating: **
HSP.DL $0.00 Down +0.00 +0.00%
Hospira CAPS Rating: ***
PFE $32.20 Up +0.02 +0.05%
Pfizer CAPS Rating: ****
PTIE $0.70 Down -0.05 -6.15%
Pain Therapeutics CAPS Rating: ***